- Home
- /
- About TargetCancer Foundation
- /
- Our Impact
Our Impact
A timeline of TCF’s impact in driving research and awareness for rare cancers
Key Milestones
A founding goal of TCF was realized as researchers published “Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets“, in Cancer Discovery, a journal of the American Association for Cancer Research. The paper details identification of potential drug targets and novel disease subtypes through in-depth genetic and cellular analysis of a large collection of biliary tract cancer cell lines, paving the way for more personalized treatments.
The work continues, and we can’t do it without you!
Uniting leaders in rare cancer and tissue-agnostic drug development to identify opportunities for cross-company collaboration.
A highly interactive, now-annual meeting that promotes collaboration between clinicians, researchers, industry, patient advocates, patients, and others to address the needs of people living with rare cancers.
Bringing rare cancer experts together with TCF community members to provide insights and answer questions on a range of rare cancer topics from clinical trial participation to genetic and genomic testing.
A cutting-edge precision oncology trial enrolling 400 patients with rare cancers and cancer of unknown primary using a remote consenting process, and providing biomarker testing and expert treatment recommendations.
Since 2015, runners participating in the Boston Marathon through Team TCF raise awareness and funds for TCF’s rare cancer research and patient support efforts.
Which has since sponsored multiple, targeted research grants leading to a cross-institution cholangiocarcinoma research collaboration.
Together with other rare cancer advocates under the National Organization for Rare Disorders (NORD) Membership umbrella. This coalition shines a light on individuals living with rare cancers and explores shared solutions.
In conjunction with (then) Vice President Biden’s National White House Cancer Moonshot Summit, TCF hosted local rare cancer patients, advocates, researchers, and drug developers to discuss their unique challenges, directly informing the White House’s efforts.
A unique, two-day meeting that brings together top clinicians and researchers to address common challenges facing people affected by gastroesophageal cancers, driving the creation of new research priorities and scientific collaborations.
Beginning a multi-year investment in research funding, which has since yielded the identification of immunotherapeutic targets and led to a clinical trial testing an existing immunotherapy against esophageal cancer at Dana-Farber Cancer Institute.
Through a research grant to the Bass lab at the Dana-Farber Cancer Institute aimed at improving understanding and treatment for this under-resourced, fast-growing rare cancer.
At Massachusetts General Hospital, leading to a first-of-its-kind cholangiocarcinoma cell line collection which was completed in 2019 and later moved into the public domain. We also hosted the first Cholangiocarcinoma Think Tank meeting this year, laying the groundwork for our long-running Think Tank program and setting the tone for future convenings.
To the Bardeesy Lab at the Massachusetts General Hospital Cancer Center, aimed at generating the basic research tools needed to understand drivers and expand treatment options for this rare cancer.
Uniting hundreds of patients, caregivers, doctors, researchers, and advocacy partners to raise awareness and funds for rare cancer research and patient support.
To drive more effective and personalized treatments for rare cancers, beginning with an initial grant from Paul to the Massachusetts General Hospital Center for Molecular Therapeutics.
